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foolish wealthy merchant whose only thought is having an
heir. The clever Callimaco therefore disguises himself as a
physician, and to gain Nicia’s faith, he performs an hilarious
uroscopic exam (Act II, Scene 6), reported in Table 1.
Machiavelli reports how easy could be for an educated
imposter to play the part of an expert doctor, without seeing
his patient. It is crucial to note the importance of Nicia’s
credulous attitude towards someone who could speak Latin,
educated in a foreign Country, asking for an absolute faith in
his previous experience. It is possible that Machiavelli took
his inspiration from the first printed medical books on
uroscopy, such as the Epiphanie Medicorum5 or the
Fasciculus Medicinae.6 In any case, he tried to denigrate the
inappropriate use of uroscopy much earlier than Thomas
Brian.7
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Classification of pediatric lupus
nephritis
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To the Editor: We read with great interest the review by
Markowitz and D’Agati1 on the 2003 International Society of
Nephrology (ISN)/Renal Pathology Society (RPS) classifica-
tion of lupus nephritis (LN).2 We agree that the new
classification has provided a standardized approach to renal
biopsy interpretation which was required to compare
outcome data across centers and facilitate intervention trials
in LN.
The authors highlight the controversy regarding the
introduction of a subclassification within diffuse LN (class IV)
Table 1 | Transcript of the play ‘La Mandragola’, relevant to uroscopy, from the original Scene 6, Act II, in Italian and Latin,
followed by English translation
CALLIMACO Avete voi el segno?
NICIA E’ l’ha Siro, sotto.
CALLIMACO Da`llo qua. Oh! questo segno mostra debilita` di rene.
NICIA Ei mi par torbiccio; eppur l’ha fatto or ora.
CALLIMACO Non ve ne maravigliate. Nam mulieris urinae sunt semper maioris grossitiei et albedinis, et minoris pulchritudinis, quam virorum. Huius autem,
inter caetera, causa est amplitudo canalium, mixtio eorum quae ex matrice exeunt cum urina.
NICIA Oh! uh! potta di san Puccio! Costui mi raffinisce in tralle mani; guarda come ragiona bene di queste cose!
CALLIMACO Io ho paura che costei non sia, la notte, mal coperta, e per questo fa l’orina cruda.
NICIA Ella tien pure addosso un buon coltrone; ma la sta quattro ore ginocchioni ad infilzar paternostri, innanzi che la se ne venghi al letto, ed e` una
bestia a patir freddo.
CALLIMACO Infine, dottore, o voi avete fede in me, o no; o io vi ho ad insegnare un rimedio certo, o no. Io, per me, el rimedio vi daro`. Se voi avrete fede
in me, voi lo piglierete; e se, oggi ad uno anno, la vostra donna non ha un suo figliolo in braccio, io voglio avervi a donare duemila ducati.
NICIA Dite pure, che´ io son per farvi onore di tutto, e per credervi piu´ che al mio confessoro.
CALLIMACO Have you got the specimen?
NICIA Siro’s got it, under his mantle.
CALLIMACO Give it to me. Oh! This specimen shows a weakness of the kidneys.
NICIA Indeed, it looks quite cloudy to me; and yet she just did it.
CALLIMACO You should not be surprised. Nam mulieris urinae sunt semper maioris grossitiei et albedinis, et minoris pulchritudinis, quam virorum. Huius
autem, inter caetera, causa est amplitudo canalium, mixtio eorum quae ex matrice exeunt cum urina. (In fact, urine from females is always thicker and whiter,
and less exquisite, than urine from males. Of such things, among others, the cause is the width of the channels, combined with the materials which exit from
the body matrix with the urine).
NICIA Oh! uh! Pussy of Saint Puccio! This man gets better and better while I listen to him; see how well he speaks about these things!
CALLIMACO I fear the patient may not be well covered at night, and perhaps this is the reason why her urine is not well matured.
NICIA She is well covered, with a good blanket, but then she’ll spend four hours on her knees threading paternosters together, before she comes to bed,
and yet she is as strong as an ox when it comes to standing the cold.
CALLIMACO Well now, sir, the question is, have you faith in me, or haven’t you; and do you want me to teach you a certain remedy or don’t you? For my
part, I’m ready to give you the cure. If you have faith in me, you’ll get it, and if your wife doesn’t have a baby in her arms by this time next year, then I’ll
be willing to give you two thousand ducats.
NICIA Go on then, tell me, because I am ready to give you credit and honors for everything, and ready to believe you more than my own confessor.
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with either segmental (‘IV-S’) or global (‘IV-G’) distribution
of lesions as published data so far has failed to show a worse
outcome between these groups. They also quote one
publication in which the authors conclude that this
subclassification ‘may not be justified.’3
Poorer renal prognosis in pediatric LN may be due to
different etiopathogenesis. We found a worse outcome in
children with class IV-G LN in our published data of 39 cases
(85% female) aged 3.3–18.0 (median 13.7) years at our single
center over 10 years.4 Patients underwent 49 percutaneous
renal biopsies at 0.1–7.8 (median 1.0) years from diagnosis of
systemic lupus erythematosus with renal and overall survival
rates of 90 and 92% respectively at a follow-up of 1.3–15.4
(median 5.5) years. In our cohort, the three most severe cases
of chronic kidney disease with estimated glomerular filtration
rate o25 ml/min/1.73 m2 were patients with diffuse global
sclerosing (class IV-G(C)) LN. Therefore, we require larger
studies of pediatric LN to evaluate progression of disease and
guide physicians on treatment.
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The Gitelman syndrome mutation,
IVS9þ1G4T, is common across
Europe
Kidney International (2007) 72, 898; doi:10.1038/sj.ki.5002504
To the Editor: In a paper published in Kidney International,
Coto et al.1,2 described a SLC12A3 mutation, IVS9þ 1G4T,
subsequently shown to result in aberrant splicing and exon
skipping. The 21 homozygote patients known so far belong
to unrelated Gypsy families from Spain, Portugal, France, and
Germany, suggesting that IVS9þ 1G4T is a shared ancestral
mutation.1,2 To provide more comprehensive data on its
molecular epidemiology in European Gypsies, we tested a
panel of 599 unrelated control subjects of Roma/Gypsy
ethnicity from Bulgaria (representing eight different sub-
isolates), Romania, Hungary, the Czech Republic, and Spain.
Amplification refractory mutation system-polymerase chain
reaction was used for screening (conditions available upon
request), with positive results verified by restriction-fragment
length polymorphism.1 We detected 12 heterozygotes,
randomly spread between sub-isolates and geographic
locations, pointing to a founder effect common to the entire
European Gypsy population. The overall carrier rate is 2%,
ranging between 0 and 7% in different sub-isolates. Given the
variable and often nonspecific clinical manifestations of
Gitelman syndrome,3 this information should facilitate the
diagnosis and management of affected Gypsy individuals.
The allelic heterogeneity of Gitelman syndrome, with over
100 mutations in SLC12A3 identified to date, has made
genotype–phenotype correlations problematic.3 The observed
clinical heterogeneity in individuals homozygous for the
same mutation points to the potential role of modifying
genes.1,4 The IVS9þ 1G4T founder mutation, with an
expected incidence of affected homozygotes of 1:10 000
across Europe (up to 1:800 in some sub-isolates), should
allow the collection of large numbers of genetically homo-
geneous patients, where phenotype diversity can be char-
acterized further and the search for modifying factors can
begin.
ACKNOWLEDGMENTS
This project was partly supported by a Western Australian Institute
for Medical Research student scholarship to ST Bouwer.
1. Coto E, Rodriguez J, Jeck N et al. A new mutation (intron 9 +1 G4T) in
the SLC12A3 gene is linked to Gitelman syndrome in Gypsies. Kidney Int
2004; 65: 25–29.
2. Riancho JA, Saro G, Sanudo C et al. Gitelman syndrome: genetic and
expression analysis of the thiazide-sensitive sodium-chloride transporter
in blood cells. Nephrol Dial Transplant 2006; 21: 217–220.
3. Riveira-Munoz E, Chang Q, Bindels R, Devuyst O. Gitelman’s syndrome:
towards genotype–phenotype correlations? Pediatr Nephrol 2007; 22:
326–332.
4. Lin SH, Cheng NL, Hsu YJ, Halperin ML. Intrafamilial phenotype variability
in patients with Gitelman syndrome having the same mutations in their
thiazide-sensitive sodium/chloride cotransporter. Am J Kidney Dis 2004;
43: 304–312.
ST Bouwer1, E Coto2, F Santos3, D Angelicheva1, D Chandler4
and L Kalaydjieva1
1Western Australian Institute for Medical Research and Centre for Medical
Research, The University of Western Australia, Perth, Western Australia,
Australia; 2Gene´tica Molecular, Hospital Central de Asturias (Maternidad),
Oviedo, Spain; 3Pediatrı´a, Hospital Central de Asturias (Maternidad), Oviedo,
Spain and 4Centre for Clinical Research in Neuropsychiatry, The University of
Western Australia, Perth, Western Australia, Australia
Correspondence: L Kalaydjieva, Laboratory of Molecular Genetics, Western
Australian Institute for Medical Research, ‘B’ Block, QEII Medical Centre,
Perth, Western Australia 6009, Australia. E-mail: luba@cyllene.uwa.edu.au.
898 Kidney International (2007) 72, 895–898
l e t t e r t o t h e e d i t o r
